Ideally, the use of KRAS mutational analysis would be most helpful if the mutation was mutually exclusive to the lung adenocarcinoma, but there also exists a possibility that the patient may develop two distinct primaries that harbor identical KRAS mutations. The gene discussed is KRAS; the disease is lung adenocarcinoma.